Involvement of I2-imidazoline binding sites in positive and negative morphine analgesia modulatory effects

European Journal of Pharmacology

Volumn 553, Issue 1-3, 2006, Pages 73-81

  Gentili, Francesco ^a   Cardinaletti, Claudia ^a   Carrieri, Antonio ^b   Ghelfi, Francesca ^a   Mattioli, Laura ^a   Perfumi, Marina ^a   Vesprini, Cristian ^a   Pigini, Maria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Diphenyzoline; I2 IBS (I2 imidazoline binding sites); I2 IBS ligands; Morphine analgesia modulation; Phenyzoline

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BENZENE DERIVATIVE; DIPHENYZOLINE; EFAROXAN; IDAZOXAN; IMIDAZOLINE I2 RECEPTOR; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; PHENYZOLINE; TRACIZOLINE; UNCLASSIFIED DRUG; YOHIMBINE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BENZOFURAN DERIVATIVE; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTOR 2; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HOT PLATE TEST; MALE; MOUSE; NEUROMODULATION; NONHUMAN; PHEOCHROMOCYTOMA CELL; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY; RECEPTOR SENSITIVITY; STRUCTURAL HOMOLOGY; TAIL FLICK TEST; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; CHO CELL; HAMSTER; METABOLISM; PAIN ASSESSMENT; RADIOASSAY; REACTION TIME;

ADRENERGIC ALPHA-ANTAGONISTS; ANALGESICS, OPIOID; ANIMALS; BENZOFURANS; CHO CELLS; CRICETINAE; IDAZOXAN; IMIDAZOLES; MALE; MICE; MODELS, MOLECULAR; MORPHINE; NALOXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; RADIOLIGAND ASSAY; REACTION TIME; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; RECEPTORS, OPIOID, MU; YOHIMBINE;

EID: 33751190283     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.031     Document Type: Article

References (49)

1. 3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn-Schmiedeberg's Arch. Pharmacol. 356 (1997) 39-47
2. 2-imidazoline ligands. Br. J. Pharmacol. 125 (1998) 175-185
3. Bousquet P. I1 receptors, cardiovascular function, and metabolism. Am. J. Hypertens. 14 (2001) 317S-321S
4. Bousquet P., Feldman J., and Schwartz J. Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines. J. Pharmacol. Exp. Ther. 230 (1984) 232-236
5. Carrieri A., Brasili L., Leonetti F., Pigini M., Giannella M., Bousquet P., and Carotti A. 2-D and 3-D modeling of imidazoline receptor ligands: insights into pharmacophore. Bioorg. Med. Chem. 5 (1997) 843-856
6. 50) of an enzymatic reaction. Biochem. Pharmacol. 22 (1973) 3099-3108
7. Dardonville C., and Rozas I. Imidazoline binding sites and their ligands: an overview of the different chemical structures. Med. Res. Rev. 24 (2004) 639-661
8. DeLean A., Munson P.J., and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235 (1978) E97-E102
9. Diaz A., Pazos A., Florez J., and Hurle M.A. Autoradiographic mapping of μ-opioid receptors during opiate tolerance and supersensitivity in the rat central nervous system. Naunyn-Schmiedeberg's Arch. Pharmacol. 362 (2000) 101-109
10. Eglen R.M., Hudson A.L., Kendall D.A., Nutt D.J., Morgan N.G., Wilson V.G., and Dillon M.P. 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol. Sci. 19 (1998) 381-390
11. Escriba P.V., Ozaita A., and Garcia-Sevilla J.A. Pharmacological characterization of imidazoline receptor proteins identified by immunologic techniques and other methods. Ann. N. Y. Acad. Sci. 881 (1999) 8-25
12. Gardmark M., Hoglund A.U., and Hammarlund-Udenaes M. Aspects on tail-flick, hot-plate and electrical stimulation tests for morphine antinociception. Pharmacol. Toxicol. 83 (1998) 252-258
13. 2-Adrenoreceptors profile modulation and high antinociceptive activity of (S)-(-)-2-[1-(biphenyl-2-yloxy)ethyl]4,5-dihydro-1H-imidazole. J. Med. Chem. 45 (2002) 32-40
14. 2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues. J. Med. Chem. 46 (2003) 2169-2176
15. 2C-subtype. J. Med. Chem. 47 (2004) 6160-6173
16. 1-receptor ligand 2-(2-biphenyl-2-yl-1-methyl-ethyl)-4,5-dihydro-1H-imidazole. Lett. Drug Des. Discov. 2 (2005) 571-578
17. Heemskerk F.M., Dontenwill M., Greney H., Vonthron C., and Bousquet P. Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem. J. Neurochem. 71 (1998) 2193-2202
18. 2-sites). Br. J. Pharmacol. 114 (1995) (Suppl.), 411P
19. 2-adrenoceptor subtypes in the antinociceptive, sedative and hypothermic action of dexmedetomidine in transgenic mice. Br. J. Pharmacol. 122 (1997) 1339-1344
20. Janumpalli S., Butler L.S., MacMillan L.B., Limbird L.E., and McNamara J.O. A point mutation (D79N) of the α2A adrenergic receptor abolishes the antiepileptogenic action of endogenous norepinephrine. J. Neurosci. 18 (1998) 2004-2008
21. Jones R.C.F., and Dimopoulos P. A new protocol for the synthesis of N(1)-unsubstituted 2-substituted 2-imidazolines. Tetrahedron 56 (2000) 2061-2074
22. Kolesnikov Y., Jain S., and Pasternak G.W. Modulation of opioid analgesia by agmatine. Eur. J. Pharmacol. 296 (1996) 17-22
23. Lakhlani P.P., MacMillan L.B., Guo T.Z., McCool B.A., Lovinger D.M., Maze M., and Limbird L.E. Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9950-9955
24. Langerman L., Zakowski M.I., Piskoun B., and Grant G.J. Hot plate versus tail flick: evaluation of acute tolerance to continuous morphine infusion in the rat model. J. Pharmacol. Toxicol. Methods 34 (1995) 23-27
25. Li G., Regunathan S., Barrow C.J., Eshraghi J., Cooper R., and Reis D.J. Agmatine an endogenous clonidine-displacing substance in the brain. Science 263 (1994) 966-969
26. Lipp J. Possible mechanism of morphine analgesia. Clin. Neuropharmacol. 14 (1991) 131-147
27. MacMillan L.B., Hein L., Smith M.S., Piascik M.T., and Limbird L.E. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 273 (1996) 801-803
28. Malmberg A.B., and Bannon A.W. Models of nociception: hot-plate, tail-flick, and formalin tests in rodents. In: Crawley J.N., Gerfen C.R., Rogawski M.A., Sibley D.R., Skolnick P., and Wray S. (Eds). Current Protocols in Neuroscience (1999), John Wiley & Sons, New York, NY 8.9.1-8.9.15
29. McMartin C., and Bohacek R.S. QXP: powerful, rapid computer algorithms for structure-based drug design. J. Comput.-Aided Mol. Des. 11 (1997) 333-344
30. Millan M.J. Descending control of pain. Prog. Neurobiol. 66 (2002) 355-474
31. Mizobe T., Maghsoudi K., Sitwala K., Tianzhi G., Ou J., and Maze M. Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat. J. Clin. Invest. 98 (1996) 1076-1080
32. Molderings G.J. Imidazoline receptors: basic knowledge, recent advances and future prospects for therapy and diagnosis. Drugs Future 22 (1997) 757-772
33. Molderings G.J., and Gothert M. Imidazoline binding sites and receptors in cardiovascular tissue. Gen. Pharmacol. 32 (1999) 17-22
34. 1 receptors modulate aqueous hydrodynamics. Curr. Eye Res. 22 (2001) 358-366
35. 2-imidazoline receptors in rat liver. Br. J. Pharmacol. 121 (1997) 901-912
36. Parini A., Moudanos C.G., Pizzinat N., and Lanier S.M. The elusive family of imidazoline binding sites. Trends Pharmacol. Sci. 17 (1996) 13-16
37. Pigini M., Bousquet P., Carotti A., Dontenwill M., Giannella M., Moriconi R., Piergentili A., Quaglia W., Tayebati S.K., and Brasili L. Imidazoline receptors: qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorg. Med. Chem. 5 (1997) 833-841
38. Raddatz R., Savic S.L., Bakthavachalam V., Lesnick J., Jasper J.R., McGrath C.R., Parini A., and Lanier S.M. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J. Pharmacol. Exp. Ther. 292 (2000) 1135-1145
39. Reynolds G.P., Boulton R.M., Pearson S.J., Hudson A.L., and Nutt D.J. Imidazoline binding sites in Huntington's and Parkinson's disease putamen. Eur. J. Pharmacol. 301 (1996) R19-R21
40. Ruggiero D.A., Regunathan S., Wang H., Milner T.A., and Reis D.J. Immunocytochemical localization of an imidazoline receptor protein in the central nervous system. Brain Res. 780 (1998) 270-293
41. Ruiz-Durantez E., Torrecilla M., Pineda J., and Ugedo L. Attenuation of acute and chronic effects of morphine by the imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline in rat locus coeruleus neurons. Br. J. Pharmacol. 138 (2003) 494-500
42. 2-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br. J. Pharmacol. 130 (2000) 146-152
43. Santos A.R.S., Gadotti V.M., Oliveira G.L., Tibola D., Paszcuk A.F., Neto A., Spindola H.M., Souza M.M., Rodrigues A.L.S., and Calixto J.B. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology 48 (2005) 1021-1034
44. Smyth D.D., and Penner S.B. Peripheral and central imidazoline receptor-mediated natriuresis in the rat. Ann. N. Y. Acad. Sci. 881 (1999) 344-357
45. Su R.B., Li J., Li X., and Qin B.Y. Down-regulation of MAO-B activity and imidazoline receptors in rat brain following chronic treatment of morphine. Acta Pharmacol. Sin. 22 (2001) 639-644
46. Tesson F., and Parini A. Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex. Eur. J. Pharmacol. 208 (1991) 81-83
47. Tesson F., Limon I., and Parini A. Tissue-specific localization of mitochondrial imidazoline-guanidinium receptive site. Eur. J. Pharmacol. 219 (1992) 335-338
48. 2-adrenoceptor-mediated mechanism in mice. Neuropsychopharmacology 25 (2001) 98-103
49. Yoburn B.C., Lutfy K., and Candido J. Species differences in μ- and δ-opioid receptors. Eur. J. Pharmacol. 193 (1991) 105-108